Diarrhea 11, malabsorptive, congenital
disease diseaseOn this page
Also known as DIAR11Intractable Diarrhoea of Infancy Syndrome
Summary
Diarrhea 11, malabsorptive, congenital (MONDO:0032857) is a disease with 1 cohort gene.
At a glance
- Cohort genes: 1
- ClinVar variants: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | diarrhea 11, malabsorptive, congenital |
| Mondo ID | MONDO:0032857 |
| OMIM | 618662 |
| UMLS | C5231449 |
| MedGen | 1684754 |
| Is cancer (heuristic) | no |
Also known as: DIAR11 · Intractable Diarrhoea of Infancy Syndrome
Data availability: 6 ClinVar variants.
Disease family
Classification path: disease › human disease › disease by body system or component › digestive system disorder › diarrheal disease › congenital diarrhea › diarrhea 11, malabsorptive, congenital
Related subtypes (11): congenital malabsorptive diarrhea 4, congenital diarrhea 6, congenital diarrhea 7 with exudative enteropathy, congenital sodium diarrhea, diarrhea 12, with microvillus atrophy, diarrhea 9, diarrhea 10, protein-losing enteropathy type, congenital secretory diarrhea, diarrhea 13, diarrhea 14, congenital, diarrhea 15, congenital
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
6 retrieved; paginated sample, class counts are floors:
3 pathogenic, 2 likely pathogenic, 1 uncertain significance
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 694448 | NC_000016.10:g.1425365_1432378del | LOC115253417 | Pathogenic | no assertion criteria provided |
| 694449 | NC_000016.10:g.1430850_1433951del | LOC115253417 | Pathogenic | no assertion criteria provided |
| 3255349 | NM_001365310.2(PERCC1):c.390C>G (p.Tyr130Ter) | PERCC1 | Pathogenic | criteria provided, single submitter |
| 2582632 | NM_001365310.2(PERCC1):c.348C>G (p.Tyr116Ter) | PERCC1 | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4073527 | NM_001365310.2(PERCC1):c.188C>G (p.Ser63Ter) | PERCC1 | Likely pathogenic | criteria provided, single submitter |
| 3235249 | NM_001365310.2(PERCC1):c.541G>A (p.Gly181Arg) | PERCC1 | Uncertain significance | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 0 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| PERCC1 | Orphanet:714490 | PERCC1-related congenital intractable malabsorptive diarrhea |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| PERCC1 | HGNC:52293 | ENSG00000284395 | A0A1W2PR82 | Protein PERCC1 | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| PERCC1 | Protein PERCC1 | Plays a critical role in intestinal function. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| PERCC1 | Other/Unknown | no | TEADIR3_omega_loop |
Expression context
Cohort genes with no expression data: 0.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| body of stomach | 1 |
| duodenum | 1 |
| stomach | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| PERCC1 | 40 | tissue_specific | yes | duodenum, body of stomach, stomach |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| PERCC1 | 52 |
Structural data
PDB: 0 · AlphaFold-only: 1 · No structure: 0
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| PERCC1 | A0A1W2PR82 | 64.66 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| enteroendocrine cell differentiation | 1 | 4213.0× | 5e-04 | PERCC1 |
| digestive tract morphogenesis | 1 | 991.3× | 0.001 | PERCC1 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| PERCC1 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | PERCC1 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| PERCC1 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: PERCC1